Skip to main content
      RT @doctorRBC: Great start to #ACR21 and great recap of the year in rheumatology.
      Positive data on tofacitinib and AS b

      Robert B Chao, MD doctorRBC

      4 years ago
      Great start to #ACR21 and great recap of the year in rheumatology. Positive data on tofacitinib and AS but still pending approval. Where would JAKinibs be in your AS treatment algorithm?🤔 @RheumNow https://t.co/cs8U33355A
      RT @ericdeinmd: #ACR21 Abst#0910 by @rheum_cat. Do TNFi ⬆️ risk of incident HTN in AxSpa?
      ⭐️PSOAS cohort: Prosp

      Eric Dein ericdeinmd

      4 years ago
      #ACR21 Abst#0910 by @rheum_cat. Do TNFi ⬆️ risk of incident HTN in AxSpa? ⭐️PSOAS cohort: Prosp study from 2003-2018 ▶️When adjusted for confounders (obesity, disease activity, NSAID use), insufficient evidence to show ⬆️ risk of HTN w TNFi https://t.co/DCZ3W8CkOa @Rheumnow
      RT @AkhilSoodMD: Exciting day at #ACR21
      I wrote an article discussing COVID 19 in #RheumatoidArthritis discussing the

      Akhil Sood MD AkhilSoodMD

      4 years ago
      Exciting day at #ACR21 I wrote an article discussing COVID 19 in #RheumatoidArthritis discussing the following abstracts 0097 by Hasseli 1445 by @NamrataRheum L04 by @rheum_cat & @rheum_covid @rheumnow #COVID19 #RA #JAK #Rituximab https://t.co/g32ZYHBjQY
      RT @ericdeinmd: #ACR21 Abst#0916. https://t.co/uc5JDVY0ud
      Your patient has had 1 yr of remission of AxSpa on Certolizuma

      Eric Dein ericdeinmd

      4 years ago
      #ACR21 Abst#0916. https://t.co/uc5JDVY0ud Your patient has had 1 yr of remission of AxSpa on Certolizumab pegol, tolerating the medication. What do you recommend @Rheumnow
      RT @_Castillo_Pedro: Dr. Thaissa Cotton on SLE + ILD and/or myositis: important given poorer outcomes. Ask pts and liste

      Pedro Castillo _Castillo_Pedro

      4 years ago
      Dr. Thaissa Cotton on SLE + ILD and/or myositis: important given poorer outcomes. Ask pts and listen to those lungs! 💠1.8 cases/100 patient years (14/551 pts in study) 💠92.9% had >=1 med-to-high titer marker 💠⬆️risk if baseline +anti KL-6, Ku, CENPB #ACR21 Abst#0330 @RheumNow
      RT @ericdeinmd: #ACR21 Abst#0916
      ⭐️AxSpa pts in remission: Full Certolizumab vs 1/2 dose vs PBO
      ▶️ 85% w/o flar

      Eric Dein ericdeinmd

      4 years ago
      #ACR21 Abst#0916 ⭐️AxSpa pts in remission: Full Certolizumab vs 1/2 dose vs PBO ▶️ 85% w/o flare in full dose, 80% in 1/2 dose, just 23% in PBO ▶️ PBO pts with NO flare STILL showed ⬆️ ASDAS, BASDAI, and CRP 🔥Would ⬇️ not d/c Cimzia! @Rheumnow https://t.co/uc5JDVY0ud #ACRBest https://t.co/fOssPlTEwR
      RT @drdavidliew: Small numbers but mirrors data from TENOR and plenty to think about here. We clearly want to see sustai

      David Liew drdavidliew

      4 years ago
      Small numbers but mirrors data from TENOR and plenty to think about here. We clearly want to see sustained remission and Ax details, but very promising! Definitely on the agenda for the @RheumNow #ACR21 GCA/PMR panel on Wed am with @LCalabreseDO @Sarah_L_Mackie @RichardPAConway
      ×